Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
81
Views
5
CrossRef citations to date
0
Altmetric
Original Research

GSG2 Promotes Development and Predicts Poor Prognosis of Ovarian Cancer

Yan Huang1 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
,
Yixuan Liu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
,
Keyu Zhu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
,
Xiaolu Ma2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China
,
Renquan Lu2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China;3 Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Meiqin Zhang1 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People’s Republic of China;2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
Pages 499-508 | Published online: 19 Jan 2021

References

  • Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.006
  • Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156. doi:10.1016/j.soncn.2019.02.00130867104
  • Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13(4):255–261. doi:10.1038/nrclinonc.2015.22426787282
  • Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet. 2017;41:139–152. doi:10.1016/j.bpobgyn.2016.12.001
  • Guan L, Lu Y. New developments in molecular targeted therapy of ovarian cancer. Discov Med. 2018;26(144):219–229.30695681
  • Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health. 2016;12(3):363–378. doi:10.2217/whe.16.4
  • Eswaran J, Patnaik D, Filippakopoulos P, et al. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci. 2009;106(48):20198. doi:10.1073/pnas.090198910619918057
  • Ghenoiu C, Wheelock MS, Funabiki H. Autoinhibition and polo-dependent multisite phosphorylation restrict activity of the histone H3 kinase haspin to mitosis. Mol Cell. 2013;52(5):734–745. doi:10.1016/j.molcel.2013.10.00224184212
  • Zhou L, Tian X, Zhu C, Wang F, Higgins JM. Polo-like kinase-1 triggers histone phosphorylation by haspin in mitosis. EMBO Rep. 2014;15(3):273–281. doi:10.1002/embr.20133808024413556
  • Wang F, Dai J, Daum JR, et al. Histone H3 thr-3 phosphorylation by haspin positions aurora B at centromeres in mitosis. Science. 2010;330(6001):231–235. doi:10.1126/science.118943520705812
  • Dai J, Higgins JMG. Haspin: a mitotic histone kinase required for metaphase chromosome alignment. Cell Cycle. 2005;4(5):665–668. doi:10.4161/cc.4.5.168315846065
  • Yu F, Jiang Y, Lu L, et al. Aurora-A promotes the establishment of spindle assembly checkpoint by priming the Haspin-Aurora-B feedback loop in late G2 phase. Cell Discov. 2017;3(1):16049. doi:10.1038/celldisc.2016.4928101375
  • Wang P, Hua X, Bryner YH, Liu S, Gitter CB, Dai J. Haspin inhibition delays cell cycle progression through interphase in cancer cells. J Cell Physiol. 2020;235(5):4508–4519. doi:10.1002/jcp.2932831625162
  • Yu F, Lin Y, Xu X, et al. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo. Int J Oncol. 2020;57(1):139–150. doi:10.3892/ijo.2020.504332319597
  • Zhu D, Gu X, Lin Z, Yu D, Wang J, Li L. HASPIN is involved in the progression of gallbladder carcinoma. Exp Cell Res. 2020;390(2):111863. doi:10.1016/j.yexcr.2020.11186331987787
  • Han X, Kuang T, Ren Y, Lu Z, Liao Q, Chen W. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo. Exp Cell Res. 2019;385(1):111605. doi:10.1016/j.yexcr.2019.11160531493385
  • Amoussou NG, Bigot A, Roussakis C, Robert JH. Haspin: a promising target for the design of inhibitors as potent anticancer drugs. Drug Discov Today. 2018;23(2):409–415. doi:10.1016/j.drudis.2017.10.00529031622
  • Zhang Y, Huang K, Cai H, Chen S, Sun D, Jiang P. The role of nucleolar spindle-associated protein 1 in human ovarian cancer. J Cell Biochem. 2020. doi:10.1002/jcb.29661
  • Gao S, Bian T, Zhang Y, Su M, Liu Y. TCF12 overexpression as a poor prognostic factor in ovarian cancer. Pathol Res Pract. 2019;215(9):152527. doi:10.1016/j.prp.2019.15252731311684
  • Zhang J, Liu X, Li C, et al. SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway. J Exp Clin Canc Res. 2020;39(1):79. doi:10.1186/s13046-020-01589-9
  • Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94(12):1313–1326. doi:10.1007/s00109-016-1475-327695879
  • Jia Y, Shi H, Cao Y, Feng W, Li M, Li X. PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling. Life Sci. 2019;233:116715. doi:10.1016/j.lfs.2019.11671531376371
  • Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6(4):353. doi:10.1158/2159-8290.CD-15-089426658964
  • Zhu X, Yan S, Xiao S, Xue M. Knockdown of ALPK2 inhibits the development and progression of ovarian cancer. Cancer Cell Int. 2020;20(1):267. doi:10.1186/s12935-020-01347-z32595416
  • Chauhan SC, Vannatta K, Ebeling MC, et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res. 2009;69(3):765. doi:10.1158/0008-5472.CAN-08-058719176398
  • Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–128. doi:10.1016/j.gene.2019.02.07630849534

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.